Source:http://linkedlifedata.com/resource/pubmed/id/16219903
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
11
|
pubmed:dateCreated |
2005-10-17
|
pubmed:abstractText |
To review the epidemiology, pathogenesis, and management of patients with alpha-antitrypsin (AAT) deficiency syndrome and compare Aralast with Prolastin, 2 of the 3 available human plasma-derived AAT agents.
|
pubmed:commentsCorrections | |
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Nov
|
pubmed:issn |
1060-0280
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
39
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
1861-9
|
pubmed:dateRevised |
2006-11-15
|
pubmed:meshHeading | |
pubmed:year |
2005
|
pubmed:articleTitle |
Aralast: a new alpha1-protease inhibitor for treatment of alpha-antitrypsin deficiency.
|
pubmed:affiliation |
Department of Pharmacy, University of Southern California, Los Angeles, CA 90089-9121, USA. slouie@usc.edu
|
pubmed:publicationType |
Journal Article,
Comparative Study,
Review
|